Conjunctivitis

DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg is approved in the US for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

BEDFORD, Mass. USA October 11, 2021 Eastern Daylight Time Ocular Therapeutix, Inc. (NASDAQ:OCUL) , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA)…